For instance, melanoma mouse models defective in IFN-γ signaling showed resistance to ICI therapy, as the tumor MHC Ι expression (which determined the efficiency of antigen presentation) depended on either type Ι or type II IFN-γ signaling (Kalbasi et al., 2020). Here, IFNG is linked to melanoma.